TY - JOUR
T1 - Clinical applications of thrombopoietin silencing
T2 - A possible therapeutic role in COVID-19?
AU - Alentado, Vincent J.
AU - Moliterno, Alison R.
AU - Srour, Edward F.
AU - Kacena, Melissa A.
N1 - Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2021/10
Y1 - 2021/10
N2 - Thrombopoietin (TPO) is most recognized for its function as the primary regulator of megakaryocyte (MK) expansion and differentiation. MKs, in turn, are best known for their role in platelet production. Research indicates that MKs and platelets play an extensive role in the pathologic thrombosis at sites of high inflammation. TPO, therefore, is a key mediator of thromboinflammation. Silencing of TPO has been shown to decrease platelets levels and rates of pathologic thrombosis in patients with various inflammatory disorders (Barrett et al, 2020; Bunting et al, 1997; Desai et al, 2018; Kaser et al, 2001; Shirai et al, 2019). Given the high rates of thromboinflammmation in the novel coronavirus 2019 (COVID-19), as well as the well-documented aberrant MK activity in affected patients, TPO silencing offers a potential therapeutic modality in the treatment of COVID-19 and other pathologies associated with thromboinflammation. The current review explores the current clinical applications of TPO silencing and offers insight into a potential role in the treatment of COVID-19.
AB - Thrombopoietin (TPO) is most recognized for its function as the primary regulator of megakaryocyte (MK) expansion and differentiation. MKs, in turn, are best known for their role in platelet production. Research indicates that MKs and platelets play an extensive role in the pathologic thrombosis at sites of high inflammation. TPO, therefore, is a key mediator of thromboinflammation. Silencing of TPO has been shown to decrease platelets levels and rates of pathologic thrombosis in patients with various inflammatory disorders (Barrett et al, 2020; Bunting et al, 1997; Desai et al, 2018; Kaser et al, 2001; Shirai et al, 2019). Given the high rates of thromboinflammmation in the novel coronavirus 2019 (COVID-19), as well as the well-documented aberrant MK activity in affected patients, TPO silencing offers a potential therapeutic modality in the treatment of COVID-19 and other pathologies associated with thromboinflammation. The current review explores the current clinical applications of TPO silencing and offers insight into a potential role in the treatment of COVID-19.
KW - COVID-19
KW - Coronavirus 2019
KW - Megakaryocytes
KW - Thromboinflammation
KW - Thrombopoietin
KW - Thrombopoietin silencing
UR - http://www.scopus.com/inward/record.url?scp=85109435551&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85109435551&partnerID=8YFLogxK
U2 - 10.1016/j.cyto.2021.155634
DO - 10.1016/j.cyto.2021.155634
M3 - Review article
C2 - 34247039
AN - SCOPUS:85109435551
SN - 1043-4666
VL - 146
JO - Cytokine
JF - Cytokine
M1 - 155634
ER -